accession stringclasses 716
values | cik stringclasses 420
values | company stringclasses 422
values | ticker stringclasses 394
values | filed_date stringdate 2026-07-21 00:00:00 2026-10-19 00:00:00 ⌀ | form stringclasses 1
value | signal stringclasses 12
values | negative bool 2
classes | file_name stringclasses 691
values | url stringlengths 44 98 |
|---|---|---|---|---|---|---|---|---|---|
0001193125-26-336867 | 1528115 | Annexon, Inc. | ANNX | 2026-08-06 | 8-K | orphan | false | d159969dex991.htm | https://www.sec.gov/Archives/edgar/data/1528115/000119312526336867/d159969dex991.htm |
0001193125-26-336670 | 1658551 | Amylyx Pharmaceuticals, Inc. | AMLX | 2026-08-06 | 8-K | topline | false | amlx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-ex99_1.htm |
0001193125-26-336670 | 1658551 | Amylyx Pharmaceuticals, Inc. | AMLX | 2026-08-06 | 8-K | breakthrough | false | amlx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-ex99_1.htm |
0001193125-26-336670 | 1658551 | Amylyx Pharmaceuticals, Inc. | AMLX | 2026-08-06 | 8-K | fast_track | false | amlx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-ex99_1.htm |
0001193125-26-336670 | 1658551 | Amylyx Pharmaceuticals, Inc. | AMLX | 2026-08-06 | 8-K | orphan | false | amlx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-ex99_1.htm |
0001171843-26-005294 | 1799448 | Aligos Therapeutics, Inc. | ALGS | 2026-08-06 | 8-K | topline | false | exh_991.htm | https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/exh_991.htm |
0001171843-26-005294 | 1799448 | Aligos Therapeutics, Inc. | ALGS | 2026-08-06 | 8-K | breakthrough | false | exh_991.htm | https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/exh_991.htm |
0001171843-26-005294 | 1799448 | Aligos Therapeutics, Inc. | ALGS | 2026-08-06 | 8-K | fast_track | false | exh_991.htm | https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/exh_991.htm |
0001104659-26-091629 | 1557746 | Aclaris Therapeutics, Inc. | ACRS | 2026-08-06 | 8-K | topline | false | acrs-20260806xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/acrs-20260806xex99d1.htm |
0001104659-26-092128 | 1557746 | Aclaris Therapeutics, Inc. | ACRS | 2026-08-06 | 8-K | clinical_hold | true | acrs-20260806xex10d1.htm | https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/acrs-20260806xex10d1.htm |
0001104659-26-092128 | 1557746 | Aclaris Therapeutics, Inc. | ACRS | 2026-08-06 | 8-K | ind | false | acrs-20260806xex10d1.htm | https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/acrs-20260806xex10d1.htm |
0001437402-26-000043 | 1437402 | ARDELYX, INC. | ARDX | 2026-08-06 | 8-K | topline | false | ardx-20260630xexhibit992.htm | https://www.sec.gov/Archives/edgar/data/1437402/000143740226000043/ardx-20260630xexhibit992.htm |
0001193125-26-336843 | 1810182 | ALX ONCOLOGY HOLDINGS INC | ALXO | 2026-08-06 | 8-K | topline | false | alxo-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/alxo-ex99_1.htm |
0001193125-26-336780 | 1098972 | AGENUS INC | AGEN | 2026-08-06 | 8-K | interim | false | agen-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1098972/000119312526336780/agen-ex99_1.htm |
0001326732-26-000055 | 1326732 | Xencor Inc | XNCR | 2026-08-05 | 8-K | interim | false | xncr-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805xexx991.htm |
0001326732-26-000055 | 1326732 | Xencor Inc | XNCR | 2026-08-05 | 8-K | fast_track | false | xncr-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805xexx991.htm |
0001628280-26-053351 | 1706431 | Vir Biotechnology, Inc. | VIR | 2026-08-05 | 8-K | topline | false | a20260805-q2ex991earningsr.htm | https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/a20260805-q2ex991earningsr.htm |
0001649094-26-000041 | 1649094 | Vaxcyte, Inc. | PCVX | 2026-08-05 | 8-K | topline | false | pcvx-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805xexx991.htm |
0001628280-26-053308 | 1347178 | Vanda Pharmaceuticals Inc. | VNDA | 2026-08-05 | 8-K | topline | false | vnda8-k852026exhibit991.htm | https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm |
0001628280-26-053308 | 1347178 | Vanda Pharmaceuticals Inc. | VNDA | 2026-08-05 | 8-K | orphan | false | vnda8-k852026exhibit991.htm | https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm |
0001628280-26-053308 | 1347178 | Vanda Pharmaceuticals Inc. | VNDA | 2026-08-05 | 8-K | pdufa | false | vnda8-k852026exhibit991.htm | https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm |
0001437749-26-025793 | 1668243 | UroGen Pharma Ltd. | URGN | 2026-08-05 | 8-K | ind | false | ex_995856.htm | https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/ex_995856.htm |
0001599298-26-000071 | 1599298 | Summit Therapeutics Inc. | SMMT | 2026-08-05 | 8-K | pdufa | false | a2026_prx0805xannounceme.htm | https://www.sec.gov/Archives/edgar/data/1599298/000159929826000071/a2026_prx0805xannounceme.htm |
0001193125-26-333820 | 1609809 | Seres Therapeutics, Inc. | MCRB | 2026-08-05 | 8-K | topline | false | d124829dex991.htm | https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/d124829dex991.htm |
0001193125-26-335056 | 873303 | Sarepta Therapeutics, Inc. | SRPT | 2026-08-05 | 8-K | clinical_hold | true | srpt-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/srpt-ex99_1.htm |
0001172052-26-000021 | 1172052 | SAFETY INSURANCE GROUP INC | SAFT | 2026-08-05 | 8-K | topline | false | saft-20260805xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1172052/000117205226000021/saft-20260805xex99d1.htm |
0001802768-26-000014 | 1802768 | Royalty Pharma plc | RPRX | 2026-08-05 | 8-K | topline | false | rprx-20260630rpplcpressxre.htm | https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260630rpplcpressxre.htm |
0001802768-26-000014 | 1802768 | Royalty Pharma plc | RPRX | 2026-08-05 | 8-K | pdufa | false | rprx-20260630rpplcpressxre.htm | https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260630rpplcpressxre.htm |
0001193125-26-335039 | 1628171 | Revolution Medicines, Inc. | null | 2026-08-05 | 8-K | breakthrough | false | rvmd-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1628171/000119312526335039/rvmd-ex99_1.htm |
0001193125-26-333853 | 2012593 | Rapport Therapeutics, Inc. | RAPP | 2026-08-05 | 8-K | topline | false | rapp-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-ex99_1.htm |
0001601830-26-000097 | 1601830 | RECURSION PHARMACEUTICALS, INC. | RXRX | 2026-08-05 | 8-K | fast_track | false | exhibit991-q0226.htm | https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/exhibit991-q0226.htm |
0001601830-26-000097 | 1601830 | RECURSION PHARMACEUTICALS, INC. | RXRX | 2026-08-05 | 8-K | orphan | false | exhibit991-q0226.htm | https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/exhibit991-q0226.htm |
0001601830-26-000097 | 1601830 | RECURSION PHARMACEUTICALS, INC. | RXRX | 2026-08-05 | 8-K | ind | false | rxrx_2q26finaldeck.htm | https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/rxrx_2q26finaldeck.htm |
0001193125-26-333813 | 1661998 | Q32 Bio Inc. | QTTB | 2026-08-05 | 8-K | topline | false | qttb-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1661998/000119312526333813/qttb-ex99_1.htm |
0001104659-26-091099 | 1377121 | Protagonist Therapeutics, Inc | PTGX | 2026-08-05 | 8-K | topline | false | tm2622272d1_ex99-2.htm | https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-2.htm |
0001104659-26-091099 | 1377121 | Protagonist Therapeutics, Inc | PTGX | 2026-08-05 | 8-K | breakthrough | false | tm2622272d1_ex99-1.htm | https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm |
0001104659-26-091099 | 1377121 | Protagonist Therapeutics, Inc | PTGX | 2026-08-05 | 8-K | fast_track | false | tm2622272d1_ex99-1.htm | https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm |
0001104659-26-091099 | 1377121 | Protagonist Therapeutics, Inc | PTGX | 2026-08-05 | 8-K | orphan | false | tm2622272d1_ex99-1.htm | https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm |
0001104659-26-091099 | 1377121 | Protagonist Therapeutics, Inc | PTGX | 2026-08-05 | 8-K | pdufa | false | tm2622272d1_ex99-1.htm | https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm |
0001279569-26-000742 | 2042694 | Primo Brands Corp | PRMB | 2026-08-05 | 8-K | topline | false | ex991.htm | https://www.sec.gov/Archives/edgar/data/2042694/000127956926000742/ex991.htm |
0001193125-26-333827 | 1936258 | NewAmsterdam Pharma Co N.V. | null | 2026-08-05 | 8-K | topline | false | nams-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-ex99_1.htm |
0001193125-26-333827 | 1936258 | NewAmsterdam Pharma Co N.V. | null | 2026-08-05 | 8-K | interim | false | nams-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-ex99_1.htm |
0001759425-26-000044 | 1759425 | Mirum Pharmaceuticals, Inc. | MIRM | 2026-08-05 | 8-K | topline | false | mirm-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm |
0001759425-26-000044 | 1759425 | Mirum Pharmaceuticals, Inc. | MIRM | 2026-08-05 | 8-K | endpoint_met | false | mirm-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm |
0001759425-26-000044 | 1759425 | Mirum Pharmaceuticals, Inc. | MIRM | 2026-08-05 | 8-K | breakthrough | false | mirm-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm |
0001759425-26-000044 | 1759425 | Mirum Pharmaceuticals, Inc. | MIRM | 2026-08-05 | 8-K | fast_track | false | mirm-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm |
0001759425-26-000044 | 1759425 | Mirum Pharmaceuticals, Inc. | MIRM | 2026-08-05 | 8-K | orphan | false | mirm-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm |
0001759425-26-000044 | 1759425 | Mirum Pharmaceuticals, Inc. | MIRM | 2026-08-05 | 8-K | pdufa | false | mirm-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm |
0001193125-26-335016 | 899460 | MANNKIND CORP | MNKD | 2026-08-05 | 8-K | topline | false | mnkd-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/mnkd-ex99_1.htm |
0001193125-26-333834 | 1815442 | Kymera Therapeutics, Inc. | KYMR | 2026-08-05 | 8-K | topline | false | kymr-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-ex99_1.htm |
0001790340-26-000088 | 1790340 | Immuneering Corp | IMRX | 2026-08-05 | 8-K | topline | false | imrx-20260805xexx991.htm | https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm |
0001193125-26-333912 | 1835579 | ImageneBio, Inc. | IMA | 2026-08-05 | 8-K | topline | false | d166048dex991.htm | https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/d166048dex991.htm |
0001193125-26-333821 | 1314102 | EyePoint, Inc. | EYPT | 2026-08-05 | 8-K | topline | false | eypt-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_1.htm |
0001193125-26-335101 | 1672619 | Enliven Therapeutics, Inc. | ELVN | 2026-08-05 | 8-K | fast_track | false | elvn-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/elvn-ex99_1.htm |
0001650664-26-000082 | 1650664 | Editas Medicine, Inc. | EDIT | 2026-08-05 | 8-K | topline | false | editasmedicinepressrelease.htm | https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/editasmedicinepressrelease.htm |
0000939767-26-000096 | 939767 | EXELIXIS, INC. | EXEL | 2026-08-05 | 8-K | topline | false | exel20260630exhibit991.htm | https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm |
0000939767-26-000096 | 939767 | EXELIXIS, INC. | EXEL | 2026-08-05 | 8-K | pdufa | false | exel20260630exhibit991.htm | https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm |
0000059478-26-000077 | 59478 | ELI LILLY & Co | LLY | 2026-08-05 | 8-K | breakthrough | false | q226lillysalesandearningsp.htm | https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm |
0001628280-26-053299 | 1562088 | Duolingo, Inc. | DUOL | 2026-08-05 | 8-K | topline | false | q2fy26duolingo6-30x26share.htm | https://www.sec.gov/Archives/edgar/data/1562088/000162828026053299/q2fy26duolingo6-30x26share.htm |
0001628280-26-053378 | 1842952 | Context Therapeutics Inc. | CNTX | 2026-08-05 | 8-K | fast_track | false | a2026aug-contextxcorpdec.htm | https://www.sec.gov/Archives/edgar/data/1842952/000162828026053378/a2026aug-contextxcorpdec.htm |
0001213900-26-085432 | 1506251 | Citius Pharmaceuticals, Inc. | CTXR | 2026-08-05 | 8-K | orphan | false | ea030037301ex99-1.htm | https://www.sec.gov/Archives/edgar/data/1506251/000121390026085432/ea030037301ex99-1.htm |
0001816590-26-000059 | 1816590 | COMPASS Pathways plc | CMPS | 2026-08-05 | 8-K | breakthrough | false | q22026pressrelease.htm | https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm |
0001213900-26-085434 | 1851484 | CITIUS ONCOLOGY, INC. | CTOR | 2026-08-05 | 8-K | orphan | false | ea030037101ex99-1.htm | https://www.sec.gov/Archives/edgar/data/1851484/000121390026085434/ea030037101ex99-1.htm |
0001193125-26-335368 | 1709941 | BioAge Labs, Inc. | BIOA | 2026-08-05 | 8-K | topline | false | bioa-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm |
0001628280-26-052877 | 1651308 | BeOne Medicines Ltd. | null | 2026-08-05 | 8-K | topline | false | exhibit991-q22026earningsr.htm | https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/exhibit991-q22026earningsr.htm |
0001628280-26-052877 | 1651308 | BeOne Medicines Ltd. | null | 2026-08-05 | 8-K | orphan | false | exhibit991-q22026earningsr.htm | https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/exhibit991-q22026earningsr.htm |
0001171843-26-005223 | 882796 | BIOCRYST PHARMACEUTICALS INC | BCRX | 2026-08-05 | 8-K | topline | false | exh_991.htm | https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm |
0001171843-26-005223 | 882796 | BIOCRYST PHARMACEUTICALS INC | BCRX | 2026-08-05 | 8-K | clinical_hold | true | exh_991.htm | https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm |
0001787306-26-000049 | 1787306 | Arcutis Biotherapeutics, Inc. | ARQT | 2026-08-05 | 8-K | topline | false | pressreleaseex991q22026.htm | https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/pressreleaseex991q22026.htm |
0001787306-26-000049 | 1787306 | Arcutis Biotherapeutics, Inc. | ARQT | 2026-08-05 | 8-K | pdufa | false | pressreleaseex991q22026.htm | https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/pressreleaseex991q22026.htm |
0001724521-26-000042 | 1724521 | Arcus Biosciences, Inc. | RCUS | 2026-08-05 | 8-K | orphan | false | a2026q28kexhibit991.htm | https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm |
0001517022-26-000050 | 1517022 | Akebia Therapeutics, Inc. | AKBA | 2026-08-05 | 8-K | interim | false | q22026pr.htm | https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/q22026pr.htm |
0001720580-26-000049 | 1720580 | Adicet Bio, Inc. | ACET | 2026-08-05 | 8-K | topline | false | acet-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-ex99_1.htm |
0001703057-26-000044 | 1703057 | AbCellera Biologics Inc. | ABCL | 2026-08-05 | 8-K | topline | false | q22026earningspressrelease.htm | https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/q22026earningspressrelease.htm |
0001193125-26-332802 | 1515673 | Ultragenyx Pharmaceutical Inc. | RARE | 2026-08-04 | 8-K | pdufa | false | rare-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-ex99_1.htm |
0001193125-26-332752 | 1863127 | Tyra Biosciences, Inc. | TYRA | 2026-08-04 | 8-K | orphan | false | tyra-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/tyra-ex99_1.htm |
0001438533-26-000062 | 1438533 | Travere Therapeutics, Inc. | TVTX | 2026-08-04 | 8-K | topline | false | a2026q2_8-kxex991.htm | https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/a2026q2_8-kxex991.htm |
0001193125-26-332736 | 1395937 | Syndax Pharmaceuticals Inc | SNDX | 2026-08-04 | 8-K | topline | false | sndx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-ex99_1.htm |
0001636282-26-000098 | 1636282 | Spyre Therapeutics, Inc. | SYRE | 2026-08-04 | 8-K | topline | false | spyre-20260630xexx991.htm | https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/spyre-20260630xexx991.htm |
0001731122-26-001012 | 1553788 | SPLASH BEVERAGE GROUP, INC. | SBEV | 2026-08-04 | 8-K | crl | true | e7825_ex10-1.htm | https://www.sec.gov/Archives/edgar/data/1553788/000173112226001012/e7825_ex10-1.htm |
0001731122-26-001012 | 1553788 | SPLASH BEVERAGE GROUP, INC. | SBEV | 2026-08-04 | 8-K | clinical_hold | true | e7825_ex10-1.htm | https://www.sec.gov/Archives/edgar/data/1553788/000173112226001012/e7825_ex10-1.htm |
0001493152-26-035995 | 1574094 | RenovoRx, Inc. | RNXT | 2026-08-04 | 8-K | orphan | false | ex99-1.htm | https://www.sec.gov/Archives/edgar/data/1574094/000149315226035995/ex99-1.htm |
0001493152-26-035995 | 1574094 | RenovoRx, Inc. | RNXT | 2026-08-04 | 8-K | ind | false | ex99-1.htm | https://www.sec.gov/Archives/edgar/data/1574094/000149315226035995/ex99-1.htm |
0001628280-26-052527 | 1396814 | Pacira BioSciences, Inc. | PCRX | 2026-08-04 | 8-K | topline | false | pcrx-06302026x991.htm | https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-06302026x991.htm |
0000950103-26-011876 | 1356090 | PRECIGEN, INC. | PGEN | 2026-08-04 | 8-K | orphan | false | dp251262_ex9901.htm | https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/dp251262_ex9901.htm |
0000078003-26-000094 | 78003 | PFIZER INC | PFE | 2026-08-04 | 8-K | topline | false | pfe-6282026xex99.htm | https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm |
0000078003-26-000094 | 78003 | PFIZER INC | PFE | 2026-08-04 | 8-K | pdufa | false | pfe-6282026xex99.htm | https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm |
0001193125-26-331556 | 1583648 | PALVELLA THERAPEUTICS, INC. | PVLA | 2026-08-04 | 8-K | topline | false | pvla-ex99_2.htm | https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_2.htm |
0001193125-26-331556 | 1583648 | PALVELLA THERAPEUTICS, INC. | PVLA | 2026-08-04 | 8-K | breakthrough | false | pvla-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm |
0001193125-26-331556 | 1583648 | PALVELLA THERAPEUTICS, INC. | PVLA | 2026-08-04 | 8-K | fast_track | false | pvla-ex99_2.htm | https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_2.htm |
0001193125-26-331556 | 1583648 | PALVELLA THERAPEUTICS, INC. | PVLA | 2026-08-04 | 8-K | orphan | false | pvla-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm |
0001104659-26-090045 | 310158 | Merck & Co., Inc. | MRK | 2026-08-04 | 8-K | topline | false | tm2621496d1_ex99-1.htm | https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm |
0001104659-26-090045 | 310158 | Merck & Co., Inc. | MRK | 2026-08-04 | 8-K | endpoint_missed | true | tm2621496d1_ex99-1.htm | https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm |
0001104659-26-090045 | 310158 | Merck & Co., Inc. | MRK | 2026-08-04 | 8-K | breakthrough | false | tm2621496d1_ex99-1.htm | https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm |
0001493152-26-035913 | 1535955 | Lipocine Inc. | LPCN | 2026-08-04 | 8-K | topline | false | ex99-1.htm | https://www.sec.gov/Archives/edgar/data/1535955/000149315226035913/ex99-1.htm |
0001193125-26-331516 | 1374690 | Larimar Therapeutics, Inc. | LRMR | 2026-08-04 | 8-K | breakthrough | false | lrmr-ex99_2.htm | https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-ex99_2.htm |
0001193125-26-331516 | 1374690 | Larimar Therapeutics, Inc. | LRMR | 2026-08-04 | 8-K | fast_track | false | lrmr-ex99_2.htm | https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-ex99_2.htm |
0001193125-26-331516 | 1374690 | Larimar Therapeutics, Inc. | LRMR | 2026-08-04 | 8-K | orphan | false | lrmr-ex99_2.htm | https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-ex99_2.htm |
0001193125-26-331516 | 1374690 | Larimar Therapeutics, Inc. | LRMR | 2026-08-04 | 8-K | pdufa | false | lrmr-ex99_2.htm | https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-ex99_2.htm |
0001193125-26-331138 | 1521036 | Lantheus Holdings, Inc. | LNTH | 2026-08-04 | 8-K | clinical_hold | true | d167446dex21.htm | https://www.sec.gov/Archives/edgar/data/1521036/000119312526331138/d167446dex21.htm |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.